| 摘要 |
FIELD: biotechnology.SUBSTANCE: invention relates to method of increasing period of time to recurrence, and can be used in medicine. Neuregulin antagonists are obtained, which are anti-NRG1 antibody siRNK or shRNK targeted NRG1, or immune-adhesine to NRG1 for administering the previously recieved anticancer therapy, in combination with therapeutic agent specified in paclitaxel, cisplatin or their combination for delay time to recurrence or prevent development of cancer cell resistance to therapeutic agent.EFFECT: invention allows to increase period of time to recurrence, which increases survival rate of patients.10 cl, 8 dwg, 1 tbl, 8 ex |
